Nature Reviews Nephrology

Papers
(The H4-Index of Nature Reviews Nephrology is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Cellular senescence: the good, the bad and the unknown397
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality356
Pathophysiology of COVID-19-associated acute kidney injury327
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors316
Mitochondrial quality control in kidney injury and repair267
Hypertension-induced cognitive impairment: from pathophysiology to public health264
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease213
The effect of HIF on metabolism and immunity204
Epidemiology of haemodialysis outcomes196
Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation192
Cisplatin nephrotoxicity: new insights and therapeutic implications185
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup185
Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection170
Trajectories of kidney function in diabetes: a clinicopathological update156
The fibrogenic niche in kidney fibrosis: components and mechanisms156
Nitric oxide signalling in kidney regulation and cardiometabolic health146
Pathogenesis of autoimmune disease136
Postoperative acute kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality Initiative and PeriOperative Quality Initiative123
Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects120
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function119
Multi-omics integration in the age of million single-cell data118
Sustainable Development Goals relevant to kidney health: an update on progress114
Role of the cGAS–STING pathway in systemic and organ-specific diseases111
Trained immunity — basic concepts and contributions to immunopathology111
Organ donation and transplantation: a multi-stakeholder call to action110
Regulated cell death pathways in kidney disease110
COVID-19 vaccination in kidney transplant recipients110
Therapeutic advances in COVID-19103
Ferroptotic mechanisms and therapeutic targeting of iron metabolism and lipid peroxidation in the kidney101
Patient-centred approaches for the management of unpleasant symptoms in kidney disease99
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence98
The gut microbiome and hypertension97
Association of metabolic dysfunction-associated fatty liver disease with kidney disease96
Extracellular vesicles in kidney disease94
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations93
Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury92
COVID-19 vaccines and kidney disease89
Glomerular hyperfiltration88
The roles of tertiary lymphoid structures in chronic diseases86
The genetics of kidney stone disease and nephrocalcinosis86
Epidemiology of peritoneal dialysis outcomes85
Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics84
The COVID-19 pandemic: consequences for nephrology83
Kidney and heart failure outcomes associated with SGLT2 inhibitor use83
Renal microvascular endothelial cell responses in sepsis-induced acute kidney injury82
Targeting innate immunity-driven inflammation in CKD and cardiovascular disease80
Advances in CRISPR therapeutics78
Health inequities and the inappropriate use of race in nephrology78
Phenotypic diversity and metabolic specialization of renal endothelial cells78
MicroRNAs in kidney injury and disease77
Pathophysiological mechanisms leading to muscle loss in chronic kidney disease77
Circular RNAs in kidney disease and cancer75
The role of immune cells and mediators in preeclampsia75
Gasdermins and pyroptosis in the kidney75
Complosome — the intracellular complement system74
COVID-19 vaccine hesitancy72
Lipidomic approaches to dissect dysregulated lipid metabolism in kidney disease72
Membranous nephropathy: new pathogenic mechanisms and their clinical implications69
Long COVID and kidney disease65
Chronic kidney disease and the global public health agenda: an international consensus65
The impact of excessive salt intake on human health64
Therapeutic trials in adult FSGS: lessons learned and the road forward63
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope62
0.043030023574829